Research programme: eye disorders therapies - CombinatoRx/Fovea

Drug Profile

Research programme: eye disorders therapies - CombinatoRx/Fovea

Alternative Names: FOV 2301

Latest Information Update: 29 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CombinatoRx; Fovea Pharmaceuticals
  • Developer Fovea Pharmaceuticals
  • Class
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic macular oedema

Most Recent Events

  • 09 Nov 2007 Preclinical trials in Diabetic macular oedema in France (Intravitreous)
  • 20 Feb 2006 Preclinical trials in Eye disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top